Core Insights - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, with upcoming participation in key investment conferences [1][2][4] - Dr. Shankar Musunuri, the CEO, will engage in discussions aimed at expanding the company's visibility and investor relations in the biotech sector [2][4] Conference Details - Dr. Musunuri will participate in the H.C. Wainwright 27 Annual Global Investment Conference from September 8-10, 2025, in New York, with a fireside chat scheduled for September 8 at 5 p.m. ET [3] - The company will also be featured in a panel discussion titled "The FDA Gauntlet: Strategies for a Successful Run at Approval" during Biotech on Tap 2025, taking place from September 24-26, 2025, in Munich, with the panel set for September 25 at 3:30 p.m. CET [3] Company Overview - Ocugen's modifier gene therapy platform aims to address significant unmet medical needs for large patient populations suffering from inherited retinal diseases and other blindness conditions, including retinitis pigmentosa and geographic atrophy [4] - The company's approach is gene-agnostic, targeting complex diseases caused by imbalances in multiple gene networks, differentiating it from traditional gene therapies [4]

Company Overview - Ocugen, Inc. is a pioneering biotechnology leader focused on gene therapies for blindness diseases, utilizing a breakthrough modifier gene therapy platform to address significant unmet medical needs for large patient populations [3]. Upcoming Events - Ocugen will host a conference call and live webcast to discuss its first quarter 2025 financial results and provide a business update on May 9, 2025, at 8:30 a.m. ET [1]. - A pre-market earnings announcement will be issued on the same day, with dial-in numbers provided for U.S. and international callers [2]. Product Development - The company is developing programs for inherited retinal diseases and blindness diseases affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [3].